Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 859-865, 2007. First published March 29, 2007; 10.1373/clinchem.2006.081679
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 081679.Supplemental data
Right arrow All Versions of this Article:
clinchem.2006.081679v1
53/5/859    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reijn, T. S.M.
Right arrow Articles by Verbeek, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reijn, T. S.M.
Right arrow Articles by Verbeek, M. M.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:859-865.)
© 2007 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid ß42 and Tau Proteins

Thierry S.M. Reijn1,2,3, Marcel Olde Rikkert2,4, Wieneke J.A. van Geel3, Danielle de Jong1 and Marcel M. Verbeek1,2,3,a

Department of1 Neurology, 2 Alzheimer Centre Nijmegen, 3 Laboratory of Pediatrics and Neurology, and 4 Department of Geriatric Medicine, Radboud University Nijmegen Medical Centre, The Netherlands.

aAddress correspondence to this author at: Department of Neurology, 830 LKN, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Fax 31-24-3668754; e-mail m.verbeek{at}cukz.umcn.nl.

Background: Cerebrospinal fluid (CSF) concentrations of amyloid ß42 (Aß42) peptides and tau proteins may serve as biomarkers for Alzheimer disease (AD). Recently, the xMAP technology has been introduced as an alternative to ELISA for measurement of these markers.

Methods: We used xMAP assays and ELISA to analyze CSF concentrations of Aß42, total tau (t-tau), and tau phosphorylated at threonine 181 (p-tau181) in samples from 69 patients with Alzheimer disease, 26 patients with vascular dementia, and 55 controls without neurological disorders.

Results: High CV values (>28%) for the ratio of xMAP:ELISA were observed for each biomarker, indicating that a constant correction factor cannot be applied to recalculate xMAP results into ELISA results. When a combination of CSF markers was used, the sensitivity, specificity, and area under the ROC curves for xMAP assays and ELISAs were not significantly different in differentiating AD patients from vascular dementia patients and controls.

Conclusions: A constant conversion factor cannot be used successfully to recalculate results obtained with xMAP assays to those from the ELISAs. With the use of analysis of a combination of Aß42, t-tau, and p-tau in CSF, however, differentiation of clinical groups is equivalent when either xMAP technology or conventional ELISA is used.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.